, Columnist
Biogen's Strange MS Quandary Requires Stronger Medicine
With a Roche blockbuster both helping and hurting, it's time for an aggressive response.
This article is for subscribers only.
Biogen Inc. is in one of the strangest situations in the pharmaceutical industry.
It's getting a small cut of the sales of another company's booming multiple sclerosis drug, but that drug is also competing directly with its own critical MS franchise. Biogen's first-quarter earnings report on Tuesday highlighted just how untenable this is and how much more aggressive management needs to be about pursuing new assets.